The role of hormonal factors and endocrine therapy in ovarian cancer

被引：7

作者：

Serkies, Krystyna ^{[1
]}

Sinacki, Marcin ^{[1
]}

Jassem, Jacek ^{[1
]}

机构：

[1] Gdanski Uniwersytet Med, Klin Onkol & Radioterapii, PL-80211 Gdansk, Poland

来源：

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2013年 / 17卷 / 01期

关键词：

ovarian cancer; endocrine therapy; estrogens; aromatase inhibitors; PEGYLATED LIPOSOMAL DOXORUBICIN; ESTROGEN-RECEPTOR MODULATORS; PLATINUM-BASED CHEMOTHERAPY; RANDOMIZED PHASE-III; HUMAN TUMOR-CELLS; AROMATASE-ACTIVITY; STEROID-RECEPTORS; TAMOXIFEN; TRIAL; CARCINOMA;

D O I：

10.5114/wo.2013.33768

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The efficacy of the second-line chemotherapy commonly used in both relapsed ovarian cancer patients and those with primary treatment failure remains unsatisfactory. This therapy has a small effect on survival, whereas associated toxicity may diminish the patient's quality of life. Hormonal factors play a role in ovarian tumorigenesis, and inhibition of the stimulating effects of estrogens may exert a clinical benefit. The role of hormonal therapy as a palliative therapeutic alternative for ovarian cancer remains undetermined. This modality may result in long-term stabilization of disease in individual patients and is frequently in tumor remission. In this article the role of hormonal factors and recent literature of various forms of hormonal therapy for ovarian cancer are presented.

引用

页码：14 / 19

页数：6

共 52 条

[1] HORMONAL PALLIATION OF CHEMORESISTANT OVARIAN-CANCER - 3 CONSECUTIVE PHASE-II TRIALS OF THE MID-ATLANTIC ONCOLOGY PROGRAM [J].

AHLGREN, JD ;

ELLISON, NM ;

GOTTLIEB, RJ ;

LALUNA, F ;

LOKICH, JJ ;

SINCLAIR, PR ;

UENO, W ;

WAMPLER, GL ;

YEUNG, KY ;

ALT, D ;

FRYER, JG .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) :1957-1968

[2] A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer [J].

Argenta, Peter A. ;

Thomas, Sajeena G. ;

Judson, Patricia L. ;

Downs, Levi S., Jr. ;

Geller, Melissa A. ;

Carson, Linda F. ;

Jonson, Amy L. ;

Ghebre, Rahel .

GYNECOLOGIC ONCOLOGY, 2009, 113 (02) :205-209

[3] Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors [J].

Arias-Pulido, Hugo ;

Smith, Harriet O. ;

Joste, Nancy E. ;

Bocklage, Therese ;

Qualls, Clifford R. ;

Chavez, Allison ;

Prossnitz, Eric R. ;

Verschraegen, Claire F. .

GYNECOLOGIC ONCOLOGY, 2009, 114 (03) :480-485

[4]

Bowman A, 2002, CLIN CANCER RES, V8, P2233

[5] Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity [J].

Braun, DP ;

Crist, KA ;

Shaheen, F ;

Staren, ED ;

Andrews, S ;

Parker, J .

AMERICAN JOURNAL OF SURGERY, 2005, 190 (04) :570-571

[6]

Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75

[7] Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro [J].

Chen, DQ ;

Hackl, W ;

Ortmann, O ;

Treeck, O .

ANTI-CANCER DRUGS, 2004, 15 (01) :55-61

[8] Aromatase expression in ovarian epithelial cancers [J].

Cunat, S ;

Rabenoelina, F ;

Daurès, JP ;

Katsaros, D ;

Sasano, H ;

Miller, WR ;

Maudelonde, T ;

Pujol, P .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 93 (01) :15-24

[9]

Didkowska J, 2011, NOWOTWORY ZLOSLIWE P

[10] Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer:: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer [J].

du Bois, A ;

Meier, W ;

Lück, HJ ;

Emons, G ;

Moebus, V ;

Schroeder, W ;

Costa, S ;

Bauknecht, T ;

Olbricht, S ;

Jackisch, C ;

Richter, B ;

Wagner, U .

ANNALS OF ONCOLOGY, 2002, 13 (02) :251-257

← 1 2 3 4 5 6 →